Yoko Murata

Possui graduação pela Faculdade de Ciências Farmacêuticas da Universidade de São Paulo(1984), mestradopelo Instituto de Pesquisas Energéticas e Nucleares(1987) e doutoradopelo Instituto de Pesquisas Energéticas e Nucleares(1995). Atualmente é diretor de laboratorio da Sun BioMedical Technologies.

Informações coletadas do Lattes em 09/10/2022

Acadêmico

Formação acadêmica

Doutorado

1992 - 1995

Instituto de Pesquisas Energéticas e Nucleares
Ano de obtenção: 1995;

Mestrado

1984 - 1987

Instituto de Pesquisas Energéticas e Nucleares
Ano de Obtenção: 1987;Bolsista do(a): Conselho Nacional de Desenvolvimento Científico e Tecnológico.

Graduação

1979 - 1984

Faculdade de Ciências Farmacêuticas da Universidade de São Paulo

Idiomas

Inglês

Compreende Bem, Fala Bem, Lê Bem, Escreve Bem.

Espanhol

Compreende Razoavelmente, Fala Pouco, Lê Razoavelmente, Escreve Pouco.

Português

Compreende Bem, Fala Bem, Lê Bem, Escreve Bem.

Japonês

Compreende Razoavelmente, Fala Razoavelmente, Lê Pouco, Escreve Pouco.

Participação em eventos

85th Annual Meeting of the Endocrine Society.Estrogen influences changes in fat metabolism with age. 2003. (Encontro).

85th Annual Meeting of the Endocrine Society.Testicular defects in aromatase knockout mice: lessons form humans. 2003. (Encontro).

9th International Congress on Obesity,. Aromatase-defecient (ArKO) mice accumulate excess adipose tissue.. 2002. (Congresso).

84th Annual Meeting fo the Endocrine Society.Clinical Findings in an untrated adult female with a novel mutation in the aromatase gene.. 2002. (Encontro).

45th Annual Scientific Meeting of the Endocrine Society of Australia.A long term follow-up of a female with aromatase deficiency. 2002. (Encontro).

83rd Annual Meeting fo the Endocrine Society.Point mutation in the CYP19 gene and its consequence.. 2001. (Encontro).

83rd Annual Meeting fo the Endocrine Society.Estradiol administration rescues the obese phenotype of the aromatase knockout (ArKO) mouse. 2001. (Encontro).

83rd Annual Meeting fo the Endocrine Society.In vitro metabolism of androstenedione in ovaries of ArKO mice.. 2001. (Encontro).

44th Annual Scientific Meeting of the Endocrine Society of Australia.Reversal of the obese phenotype of the aromatase knockout (ArKO) mouse via adminstration of 17beta-estradiol.. 2001. (Encontro).

44th Annual Scientific Meeting of the Endocrine Society of Australia.Oestrogen deficiency in the aromatase knockout (ArKO) mouse leads to lipid accumulation in the liver. 2001. (Encontro).

11th International Congress of Endocrinology ICE 2000.. . Obesity: the phenotype of aromatase knock-out (ArKO) mice.. 2000. (Congresso).

52nd Yamada Conference, International Symposium on Molecular Steroidogenesis..Aromatase knockout (ArKO) mice have an adipose phenotype. 1999. (Simpósio).

81st Annual Meeting of The Endocrine Society.The adipose phenotype of aromatase knockout (ArKO) mice. 1999. (Encontro).

8th Annual Scientific Meeting of the Australasian Society for the Study of Obesity.Obesity: the phenotype of aromatase knockout (ArKO) mice.. 1999. (Encontro).

New Horizons in Breast Cancer Research.Elevated insulin levels in obese ARKO (Aromatase knockout) mice.. 1998. (Outra).

Congress of ALASBIMN. Recombinant human thyrotropin (rec-hTSH): development of a biotechnology product for diagnostic and therapeutic use.. 1995. (Congresso).

XX Annual Meeting of Biochemistry and Molecular Biology Society.Physiological, imunological and biological characterization of recombinant human growth hormone. 1995. (Encontro).

Symposium on Glycoprotein Hormones: Structure, Function and Clinical Implications.The role of sulfation and sialylation on the bioactivity and metabolic clearance rate of recombinant human TSH (rhTSH) and rhTSHb-hCGb carboxy terminus extension peptide chimera.. 1993. (Simpósio).

Symposium on Glycoprotein Hormones: Structure, Function and Clinical Implications.Differential roles of the terminal monosaccharides of recombinant TSH in its in vitro and in vivo bioactivity.. 1993. (Simpósio).

Symposium on Glycoprotein Hormones: Structure, Function and Clinical Implications.Regulation and expression of thyroid-stimulating hormone (TSH). 1993. (Simpósio).

75 th Annual Endocrine Society Meeting.A TSH-hCG beta carboxy terminus extension peptide (CETP) chimera is fully biologicaly active and prolongs the plasma half-life of TSH.. 1993. (Encontro).

NIH Research Festival.Strructure-function studies of recombinant and pituitary human thyrotropin. The role of carbohydrates, charge and size im hormone bioactivity.. 1993. (Outra).

XX Annual Meeting of Biochemisty and Molecular Biology Society.Isolation and purification of biosynthetic human growth hormone expressed in tranformed E. coli cells. 1991. (Encontro).

VI Pan American Biochemical Soecieties Congress. Immunogenic aspects of Bothrops jararaca venom irradiated with 60 Co rays.. 1990. (Congresso).

, III Symposium on Animal, Plant and Microbial Toxins,.Gamma irradiation reduces the toxic activities of Crotalus durissus terrificus venom but does not affect their immunogenic activities. 1990. (Simpósio).

. III Symposium on Animal, Plant and Microbial Toxins.Attenuation of Bothrops jararaca venom by the ionizing radiation.. 1990. (Simpósio).

V Annual Meeting of Experimental Biology Societies Federation..Effects of gamma radiation on Bothrops jararaca venom: biological and enzimatic activities.. 1990. (Encontro).

V Annual Meeting of Experimental Biology Societies Federation.Biodistribution studies of crotoxin 125I in mice.. 1990. (Encontro).

. III General Nuclear Energy Congress. Gamma radiation effects on Bothrops jararaca venom.. 1989. (Congresso).

Butantan Institute 1989 Retrospective.gamma radiation treatment on rattlesnake venom. 1989. (Outra).

II General Nuclear Energy Congress. Size exclusion chromatography analysis on 60 Co irradiated rattlesnake venom sample.. 1988. (Congresso).

IV Pediatric Infectology Congress. Bacteremy frequency and agents sensitivity in-patient children at Hospital of University of São Paulo. 1984. (Congresso).

III Brazilian Pediatric Infectology Congress. Ethiologic studies of acute diarrhea in a community. 1983. (Congresso).

Participação em bancas

MURATA, Y.. qualificacao para doutorado. 2006. Faculdade de Ciências Farmacêuticas da Universidade de São Paulo.

Produções bibliográficas

MURATA, Y. . Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy.. Menopause, v. 12, n.2, p. 210-215, 2005.
MURATA, Y. . Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse. Horm Metab Res., v. 37, n.1, p. 26-31, 2005.
MURATA, Y. . Differential expression of factors involved in fat metabolism with age and the menopause transition.. Maturitas, v. 51, n.3, p. 299-306, 2005.
MURATA, Y. . Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.. Cancer Res, v. 65, n.24, p. 11762-11770, 2005.
MURATA, Y. . Dysmetabolic Syndrome in a man with a novel mutation of the aromatase Gene: Effects of testosterone, alendronate and estradiol treatment. J. Clin. Endo. Metab., v. 89, n.1, p. 61-70, 2004.
MURATA, Y. . Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse.. Endocrinology, v. 144, n.4, p. 1474-1480, 2003.
MURATA, Y. . The aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol homeostasis.. Endocrinology, v. 144, n.9, p. 3895-3903, 2003.
MURATA, Y. . Effect of estrogen deficiency in the male: the ArKO mouse model.. Mol. Cell Endo., v. 193, p. 7-12, 2002.
MURATA, Y. . Ligands for the peroxisomal proliferator-activated receptor gamma and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose.. Endocrinology, v. 143, n.8, p. 2863-2871, 2002.
MURATA, Y. . A augments voltage-gated Ca2+ currents and synergistically increases growth hormone (GH) secretion with GH-releasing hormone in primary cultured ovine somatotropes.. Endocrinology, v. 143, n.12, p. 4609-4619, 2002.
MURATA, Y. . Recombinant thyrotropin containing a -subunit chimera with the human chorionic gonadotropin- carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioactivity and metabolic clearance.. Endocrinology, v. 136, n.9, p. 3839-3848, 1995.
MURATA, Y. . The use of recombinant human growth hormone for radioiodination and standard preparation in radioimmunoassay. J. Immunological Meth., v. 159, p. 269-274, 1993.
MURATA, Y. . Terminal sulfation and sialylation in thyrotropin bio-activity: characterization of bovine (bTSH) and recombinant human (rhTSH) TSH isoforms.. J.Endocrinol. Invest., v. 16, p. 2-6, 1993.
MURATA, Y. . Detoxification of the crotoxin complex by gamma radiation. Braz J Med Biol Res., v. 25, n.2, p. 103-113, 1992.
MURATA, Y. . Utilization of DNA-recombinant techniques for the preparation of radioimmunoassay reagents for pituitary hormones. Developments in radioimmunoassay and related procedures. IAEA-SM-324/67, p. 197-204, 1992.
MURATA, Y. . Growth hormone production by DNA-recombinant techniques.. Rev. Hosp. Clin. Fac. Med. S. Paulo, v. 45, n.6, p. 241-243, 1990.
MURATA, Y. . Size exclusion chromatography analysis on 60Co irradiated rattlesnake venom sample São Paulo. Publicacao IPEN 153, 1988.
MURATA, Y. . Effects of gamma radiation on Crotalus durissus terrificus venom: antigenic aspects.. Publicacao IPEN 154, 1988.
MURATA, Y. . Effects of gamma radiation on Crotalus durissus terrificus venom: antigenic aspects.. Arq. Biol. Tecnol, v. 31, n.1, p. 124, 1988.
MURATA, Y. . Effects of gamma radiation on Crotalus durissus terrificus venom.. Arq. Biol. Tecnol, v. 30, n.1, p. 196, 1987.

Histórico profissional

Endereço profissional

Sun BioMedical Technologies. , 1539 N China Lake Blvd, suite A, 93555 - Ridgecrest, - Estados Unidos, Telefone: () 7605493139

Experiência profissional

2004 - Atual

Sun BioMedical Technologies

Vínculo: , Enquadramento Funcional: diretor de laboratorio

Atividades

Pesquisa e desenvolvimento .,Linhas de pesquisa

1998 - 2000

Prince Henry's Institute of Medical Research

Vínculo: , Enquadramento Funcional: research officer, Carga horária: 40

Atividades

Direção e administração, .,Cargo ou função, lab manager.

1987 - 1992

Comissão Nacional de Energia Nuclear

Vínculo: Celetista, Enquadramento Funcional: pesquisador, Regime: Dedicação exclusiva.

Atividades

Pesquisa e desenvolvimento .,Linhas de pesquisa

1992 - 1994

National Institute Of Health

Vínculo: bolsista doutorado, Enquadramento Funcional: special volunteer, Carga horária: 40

Atividades

Estágios , NIDDK, .,Estágio realizado, Prof. Weintraub lab, TSH.

1981 - 1985

Hospital Universitário da Universidade de São Paulo - HU-USP

Vínculo: Celetista, Enquadramento Funcional: tecnica de laboratorio, Carga horária: 40

Atividades

Serviços técnicos especializados .,Serviço realizado, microbiologia.

1980 - 1981

Faculdade de Ciências Farmacêuticas da Universidade de São Paulo

Vínculo: Celetista, Enquadramento Funcional: tecnica de laboratorio, Carga horária: 40

Atividades

Pesquisa e desenvolvimento .,Linhas de pesquisa